Clinical treatment for hepatitis C reverses CYP2C19 inhibition.
Leandro Francisco PippaCarolina Pinto VieiraJuciene Aparecida CarisAdriana RochaCamile Prates GarciaRosamar Eulira Fontes RezendeVera Lucia LanchotePublished in: British journal of clinical pharmacology (2021)
Both groups presented different MRs before and after treatment with DAAs, evidencing that CYP2C19 inhibition during inflammation was at least partially reversed after DAA treatment. Groups 1 and 2 were also found to be different in phase 1 but not phase 2, showing that CYP2C19 metabolic activity does not differ between groups after DAA treatment.
Keyphrases